

Appendix D

Annotated Bibliography

This Annotated Bibliography contains an expanded listing of references, with more references than those cited in the text of the 2022 edition. The references arranged in descending date order and alphabetically by last name of first author by the following user topics of interest:

- Colorectal Cancer Screening interventions and Systematic Reviews
- Colorectal Cancer Screening in Rural Populations
- FIT or High-Sensitivity FOBT Tests
- Mailed FIT and Colorectal Cancer Screening Outreach
- Follow-Up of Abnormal FIT or FOBT Results
- Multitarget Stool DNA (mt-sDNA)
- Colorectal Cancer Screening Guidelines & Statistics
- Social Risk Factors in Colorectal Health
- Patient Navigation Role in CRC Screening
- Electronic Health Records
- Practice Management
- Cancer Prevention
- Costs & Cost Effectiveness

The references highlighted in yellow are references that are footnoted in the 2022 edition. References highlighted in cyan are references footnoted in the *Steps Guide Follow-up of Abnormal Stool Results Brief*.

Colorectal Cancer Screening Interventions and Systematic Reviews

1. Cancer Screening: Multicomponent Interventions—Colorectal Cancer. The Community Guide. <https://www.thecommunityguide.org/findings/cancer-screening-multicomponent-interventions-colorectal-cancer>. Last updated September 30, 2020. Accessed July 27, 2021. (Reference #0)
2. Virtual colonoscopy. National Institute of Diabetes and Digestive and Kidney Diseases. Accessed March 30, 2021. <https://www.niddk.nih.gov/health-information/diagnostic-tests/virtual-colonoscopy> (Brief Reference #15)
3. Colonoscopy. National Institute of Diabetes and Digestive and Kidney Diseases. Accessed March 30, 2021. <https://www.niddk.nih.gov/health-information/diagnostic-tests/colonoscopy> (Brief Reference #16)
4. Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. Screening for Colorectal Cancer: An Evidence Update for the US Preventive Services Task Force. Evidence Synthesis No. 202. Agency for Healthcare Research and Quality; 2021. AHRQ publication 20-05271-EF-1. (Reference #29)
5. Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. Published May 18, 2021. (Reference #30) doi:10.1001/jama.2021.4417
6. Mast C, Munoz del Rio A, Heist T. Cancer Screenings are Still Lagging. *Epic Health Research Network*. (2020). Retrieved from <https://ehrn.org/articles/cancer-screenings-are-still-lagging>. Last updated June 9, 2021. Accessed August 1, 2021.
7. Carrasquillo, O., Seay, J., Jhaveri, V., Long, T., Kenya, S., Thomas, E., Sussman, D., Trevil, D., Koru-Sengul, T., & Kobetz, E. (2020). Increasing uptake of evidence-based screening services through a community health worker-delivered multimodality program:

Appendix D

Annotated Bibliography

- study protocol for a randomized pragmatic trial. *Trials*. 2020;21(1):368. DOI: 10.1186/s13063-020-4213-7. PMID: 32349789. PMCID: PMC7191705.
8. Cooper JA, Ryan R, Parsons N, Stinton C, Marshall T, Taylor-Phillips S. The use of electronic healthcare records for colorectal cancer screening referral decisions and risk prediction model development. *BMC Gastroenterology*. 2020;20(1):78. DOI: 10.1186/s12876-020-01206-1. PMID: 32213167. PMCID: PMC7093989.
 9. Joseph DA, King JB, Dowling NF, Thomas CC, Richardson LC. *Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018*. MMWR Morb Mortal Wkly Rep 2020;69:253–259. DOI: <http://dx.doi.org/10.15585/mmwr.mm6910a1>
 10. Khalili F, Najafi B, Mansour-Ghanaei F, Yousefi M, Abdollahzad H, Motlagh A. Cost-effectiveness analysis of colorectal cancer screening: a systematic review. *Risk Manage Healthcare Policy*. 2020;13:1499 (Reference #8)
 11. Printz C. Cancer screenings decline significantly during pandemic. *Cancer*. 2020;126:3894-3895. 10.1002/cncr.33128.
 12. Bravo RL, Kietzman KG, Toy P, Duru OK, Wallace SP. Linking primary care and community organizations to increase colorectal cancer screening rates: the HAPPI project. *Salud Publica de Mexico*. 2019;61(4):427-435. DOI: 10.21149/9450. PMID: 31430085.
 13. Chen H, Li N, Ren J, et al. Participation and yield of a population-based colorectal cancer screening programme in China. *Gut*. 2019;68(8):1450-1457. DOI: 10.1136/gutjnl-2018-317124. PMID: 30377193.
 14. Gwede CK, Sutton SK, Chavarria EA, et al. A culturally and linguistically salient pilot intervention to promote colorectal cancer screening among Latinos receiving care in a Federally Qualified Health Center. *Health Education Research*. 2019;34(3):310-320. DOI: 10.1093/her/cyz010. PMID: 30929015. PMCID: PMC7868960.
 15. Jodal HC, Helsingen LM, Anderson JC, Lytvyn L, Vandvik PO, Emilsson L. Colorectal cancer screening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network metaanalysis. *BMJ Open*. 2019;9(10):e032773. DOI: 10.1136/bmjopen-2019-032773. PMID: 31578199. PMCID: PMC6797379.
 16. O'Leary MC, Lich KH, Gu Y, et al. Colorectal cancer screening in newly insured Medicaid members: a review of concurrent federal and state policies. *BMC Health Services Research*. 2019;19(1):298. DOI: 10.1186/s12913-019-4113-2. PMID: 31072316. PMCID: PMC6509857.
 17. Wender RC, Brawley OW, Fedewa SA, Gansler T, Smith RA. A blueprint for cancer screening and early detection: Advancing screening's contribution to cancer control. *CA: A Cancer Journal for Clinicians*. 2019;69(1):50-79. DOI: 10.3322/caac.21550. PMID: 30452086.
 18. Desai P, Lampe J, Bakre S, Basha R, Jones H, Vishwanatha J. Evidence-based approaches to reduce cancer health disparities: Discover, develop, deliver, and disseminate. *Journal of Carcinogenesis*. 2018;17(1):1. DOI: 10.4103/jcar.JCar_13_17. PMID: 29643743. PMCID: PMC5883827.
 19. Dougherty MK, Brenner AT, Crockett SD, et al. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis. *JAMA Intern Med*. 2018;178(12):1645-1658. DOI: 10.1001/jamainternmed.2018.4637. PMID: 30326005; PMCID: PMC6583619.
 20. Eberth JM, Thibault A, Caldwell R, et al. A statewide program providing colorectal cancer screening to the uninsured of South Carolina. *Cancer*. 2018;124(9):1912-1920. doi:10.1002/cncr.31250 (Reference #72)

Appendix D

Annotated Bibliography

21. Mackey, TA. Approaches to Increase Colorectal Cancer Screening Rates: Key Information for the Primary Care Provider. *Journal of Family Practice*. 2018;67:S73-S81. PMID: 30137058.
22. Petrik AF, Le T, Keast E, et al. Predictors of Colorectal Cancer Screening Prior to Implementation of a Large Pragmatic Trial in Federally Qualified Health Centers. *Journal of Community Health*. 2018;43(1):128-136. DOI: 10.1007/s10900-017-0395-7. PMID: 28744716. PMCID: PMC5767531.
23. Volk RJ, Leal VB, Jacobs LE, et al. From guideline to practice: New shared decision-making tools for colorectal cancer screening from the American Cancer Society. *CA: A Cancer Journal for Clinicians*. 2018;68(4):246-249. DOI: 10.3322/caac.21459. PMID: 29846954. PMCID: PMC6192545.
24. Wilkins T, McMechan D, Talukder A. Colorectal Cancer Screening and Prevention. *American Family Physician*. 2018;97(10):658-665. PMID: 29763272.
25. Inadomi JM. Screening for colorectal neoplasia. *N Engl J Med*. 2017;376(2):149-156. DOI:10.1056/NEJMcpl512286. PMID: 28076720.
26. Pignone M, Miller DP Jr. Using Outreach to Improve Colorectal Cancer Screening. *JAMA*. 2017;318(9):799-800. DOI: 10.1001/jama.2017.10606. PMID: 28873142.
27. Uy C, Lopez J, Trinh-Shevrin C, Kwon SC, Sherman SE, Liang PS. Text Messaging Interventions on Cancer Screening Rates: A Systematic Review. *Journal of Medical Internet Research*. 2017;19(8):e296. DOI: 10.2196/jmir.7893. PMID: 28838885. PMCID: PMC5590008.
28. Lin JS, Piper MA, Perdue LA, Rutter C, Webber EM, O'Connor E, Smith N, Whitlock EP. Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 135. AHRQ Publication No. 14-05203-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016. (Reference #38)
29. Wools A, Dapper EA, de Leeuw JRJ. Colorectal cancer screening participation: a systematic review. *European Journal of Public Health*. 2016;26(1):158-168. DOI: 10.1093/eurpub/ckv148. PMID: 26370437.
30. Elfant AB. Hot Topics in Primary Care: Colorectal Cancer Screening. *Journal of Family Practice*. 2015;64(12):S10-S15. PMID: 26845007.
31. Liang PS, Wheat CL, Abhat A, Brenner AT, et al. Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years. *Am J Gastroenterol*. 2016 Jan;111(1):105-14. doi: 10.1038/ajg.2015.367. Epub 2015 Nov 3. PMID: 26526080; PMCID: PMC4887132. (Reference #34)
32. Triantafyllidis J, Vagianos C, Malgarinos G. Colonoscopy in Colorectal Cancer Screening: Current Aspects. *Indian Journal of Surgical Oncology*. 2015;6(3):237-250. DOI: 10.1007/s13193-015-0410-3. PMID: 27217671. PMCID: PMC4856683.
33. Davis T, Arnold C, Rademaker A, et al. Improving colon cancer screening in community clinics. *Cancer*. 2013;119(21):3879-3886. doi: 10.1002/cncr.28272; 10.1002/cncr.28272. (Reference #89)
34. Gwede CK, Davis SN, Quinn GP, et al. Making it work: Health care provider perspectives on strategies to increase colorectal cancer screening in federally qualified health centers. *Cancer Educ*. 2013;28(4):777-783. doi: 10.1007/s13187-013-0531-8; 10.1007/s13187-013-0531-8. (Reference #88)
35. Sarfaty M, Doroshenk M, Hotz J, et al. Strategies for expanding colorectal cancer screening at community health centers. *CA Cancer J Clin*. 2013;63(4):221-231. doi: 10.3322/caac.21191; 10.3322/caac.21191. (Reference #58)
36. Colorectal cancer screening in community health centers: Multi-organizational effort to improve links of care. [NCCRT Meeting Report]. September 16, 2013. (Reference #62)

Appendix D

Annotated Bibliography

37. *Increasing colorectal cancer screening: An action guide for working with health systems.* Atlanta: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2013. (Reference #91)
38. Presented at the Community Health Applied Research (CHARN) Steering Committee meeting, August 1, 2013; Washington, D.C. (Reference #85)
39. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: A randomized clinical trial of competing strategies. *Arch Intern Med.* 2012;172(7):575-582. doi: 10.1001/archinternmed.2012.332; 10.1001/archinternmed.2012.332. (Reference #35)
40. Lasser KE, Murillo J, Lisboa S, et al. Colorectal cancer screening among ethnically diverse, low-income patients: A randomized controlled trial. *Arch Intern Med.* 2011;171(10):906-912. doi: 10.1001/archinternmed.2011.201; 10.1001/archinternmed.2011.201. (Reference #57)
41. Potter MB, Walsh JM, Yu TM, Gildengorin G, Green LW, McPhee SJ. The effectiveness of the FLU-FOBT program in primary care a randomized trial. *Am J Prev Med.* 2011;41(1):9-16. doi: 10.1016/j.amepre.2011.03.011; 10.1016/j.amepre.2011.03.011. (Reference #69)
42. Rohweder C, Wolf M, Schenck A, Prasad V, Diehl S, eds. *Options for increasing colorectal cancer screening rates in North Carolina community health centers.* Chapel Hill, NC: UNC Lineberger Comprehensive Cancer Center; 2011. (Reference #68)
43. Tarasenko YN, Wackerbarth SB, Love MM, Joyce JM, Haist SA. Colorectal cancer screening: Patients' and physicians' perspectives on decision-making factors. *J Cancer Educ.* 2011;26(2):285-293. doi: 10.1007/s13187-010-0145-3; 10.1007/s13187-010-0145-3. (Reference #55)
44. Sifri R, Wender R, Lieberman D, et al. Developing a quality screening colonoscopy referral system in primary care practice: A report from the national colorectal cancer roundtable. *CA Cancer J Clin.* 2010;60(1):40-49. doi: 10.3322/caac.20048; 10.3322/caac.20048. (Reference #53)
45. Comparison of bowel preparations for colonoscopy http://www.med.umich.edu/1info/FHP/practiceguides/adult.cancer/bowel_prep_comparison.pdf. Updated January 2009. Accessed April 4, 2014. (Reference #82)
46. Graser A, Stieber P, Nagel D, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. *Gut.* 2009;58(2):241-248. doi: 10.1136/gut.2008.156448; 10.1136/gut.2008.156448.
47. Lasser KE, Murillo J, Medlin E, et al. A multilevel intervention to promote colorectal cancer screening among community health center patients: Results of a pilot study. *BMC Fam Pract.* 2009;10:37-2296-10-37. doi: 10.1186/1471-2296-10-37; 10.1186/1471-2296-10-37 (Reference #66)
48. Farmer MM, Bastani R, Kwan L, Belman M, Ganz PA. Predictors of colorectal cancer screening from patients enrolled in a managed care health plan. *Cancer.* 2008;112(6):1230-1238. doi: 10.1002/cncr.23290; 10.1002/cncr.23290. (Reference #86)
49. Lasser KE, Ayanian JZ, Fletcher RH, Good MJ. Barriers to colorectal cancer screening in community health centers: A qualitative study. *BMC Fam Pract.* 2008;9:15-2296-9-15. doi: 10.1186/1471-2296-9-15; 10.1186/1471-2296-9-15. (Reference #54)
50. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: A targeted, updated systematic review for the U.S. preventive services task force. *Ann Intern Med.* 2008;149(9):638-658.

Appendix D

Annotated Bibliography

51. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: A decision analysis for the US Preventive Services Task Force. *Ann Intern Med.* 2008;149(9):659-669.
52. Myers R, Sarfaty M. Various aspects of colorectal cancer screening. *Legislative Budget and Finance Committee: A Joint Committee of the Pennsylvania General Assembly.* January 2007.
53. A practical guide to increasing screening colonoscopy: Proven methods for health care facilities to prevent colorectal cancer deaths. Cancer Prevention and Control Program, Bureau of Chronic Disease Prevention and Control. The New York City Department of Health and Mental Hygiene and New York Citywide Colon Cancer Control Coalition. November 2006. (Reference #50)
54. Seeff LC, Manninen DL, Dong FB, et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the united states? *Gastroenterology.* 2004;127(6):1661- 1669. (Reference #74)
55. Bastani R, Gallardo N, Maxwell A. Barriers to colorectal cancer screening among ethnically diverse high- and average-risk individuals. *J Psychosoc Oncol.* 2001;19(3):65-84. (Reference #56)
56. Burt RW. Colon cancer screening. *Gastroenterology.* 2000;119(3):837-853. (Reference #49)

Colorectal Cancer Screening in Rural Populations

1. Hirko KA, Lennon SA, Lucas T, et al. Improving Colorectal Cancer Screening in a Rural Setting: A Randomized Study. *American Journal of Preventive Medicine.* 2020;59(3):401-411. DOI: 10.1016/j.amepre.2020.03.019. PMID: 32684359.
2. Yabroff KR, Han X, Zhao J, Nogueira L, Jemal A. Rural cancer disparities in the United States: A multilevel framework to improve access to care and patient outcomes. *JCO Oncology Practice.* 2020;16(7):409-413. DOI: 10.1200/OP.20.00352. PMID: 32574130.
3. Schlauderaff P, Baldino T, Graham KC, et al. Colorectal cancer screening in a rural US population. *International Journal of Health Governance, Bingley.* 2017;22(4):283-291. DOI: 10.1108/IJHG-05-2017-0021.

FIT or High-Sensitivity FOBT Tests

1. Fecal occult blood test (FOBT). US National Library of Medicine. Updated July 31, 2020. Accessed March 30, 2021. <https://medlineplus.gov/lab-tests/fecal-occult-blood-test-fobt/> (Brief Reference #11)
2. Selby K, Jensen CD, Levin TR, et al. Program Components and Results From an Organized Colorectal Cancer Screening Program Using Annual Fecal Immunochemical Testing [published online ahead of print, 2020 Sep 30]. *Clin Gastroenterol Hepatol.* 2020;S1542-3565(20)31372-0. doi:10.1016/j.cgh.2020.09.042 (Reference #77)
3. Roth JA, deVos T, Ramsey SD. Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing. *American Health & Drug Benefits.* 2019;12(5):256-262. PMID: 32015794. PMCID: PMC6979046.
4. Levin TR, Corley DA, Jensen CD, et al. Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population.

Appendix D

Annotated Bibliography

Gastroenterology 2018;155:1383–1391.

DOI:<https://doi.org/10.1053/j.gastro.2018.07.017> (Reference #5)

5. Libby G, Fraser CG, Carey FA, et al. Occult blood in faeces is associated with all-cause and non-colorectal cancer mortality. *Gut* 2018;67:2116-2123. (Brief Reference #22)
6. Luque JS, Wallace K, Blankenship BF, et al. Correction to: Formative Research on Knowledge and Preferences for Stool-based Tests compared to Colonoscopy: What Patients and Providers Think. *Journal of Community Health*. 2018;43(6):1093. DOI: 10.1007/s10900-018-0534-9. PMID: 29882181.
7. Yu C, Skootsky S, Grossman M, et al. A Multi-Level Fit-Based Quality Improvement Initiative to Improve Colorectal Cancer Screening in a Managed Care Population. *Clinical and Translational Gastroenterology*. 2018;9(8):177. DOI: 10.1038/s41424-018-0046-z. PMID: 30177700. PMCID: PMC6120887.
8. Robertson, DJ; Lee, JK; Boland, RC; Dominitz, JA; Giardiello, FM; Johnson, DA, et al. Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer, *American Journal of Gastroenterology*: January 2017 - Volume 112 - Issue 1 - p 37-53 doi: 10.1038/ajg.2016.492. (Brief Reference #18)
9. Salimzadeh H, Bishehsari F, Sauvaget C, et al. Feasibility of Colon Cancer Screening by Fecal Immunochemical Test in Iran. *Archives of Iranian Medicine (AIM)*. 2017;20(12):726-733. PMID: 29664311.
10. Bresalier RS, Kopetz S, Brenner DE. Blood-based tests for colorectal cancer screening: do they threaten the survival of the FIT test? *Dig Dis Sci*. 2015;60(3):664-71. DOI: 10.1007/s10620-015-3575-2. PMID: 25680874.
11. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. *Ann Intern Med*. 2014;160(3):171. DOI: 10.7326/M13-1484. PMID: 24658694. PMCID: PMC4189821.
12. Gupta S, Halm EA, Rockey DC, et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: A randomized clinical trial. *JAMA Intern Med*. 2013;173(18):1725- 1732. doi: 10.1001/jamainternmed.2013.9294. (Reference #87)
13. Potter MB. Delivering high quality stool blood testing in primary care. [Powerpoint presentation]. November 13, 2013.
14. Tao S, Seiler CM, Ronellenfitsch U, Brenner H. Comparative evaluation of nine faecal immunochemical tests for the detection of colorectal cancer. *Acta Oncologica*. Vol. 52, Iss. 8, 2013. (Reference #39)
15. Grazzini G, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG, et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? *Br J Cancer*. 2009;100(2):259- 265. (Brief Reference #7)
16. Potter MB, Phengrasamy L, Hudes ES, McPhee SJ, Walsh JM. Offering annual fecal occult blood tests at annual flu shot clinics increases colorectal cancer screening rates. *Ann Fam Med*. 2009;7(1):17-23. doi: 10.1370/afm.934; 10.1370/afm.934. (Reference #70)
17. Smith A, Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. *Cancer*. 2006;107(9): 2152–2159. (Reference #40)
18. Collins JF, Lieberman DA, Durbin TE, Weiss DG, Veterans Affairs Cooperative Study #380 Group. Accuracy of screening for fecal occult blood on a single stool sample obtained by

Appendix D

Annotated Bibliography

digital rectal examination: A comparison with recommended sampling practice. *Ann Intern Med.* 2005;142(2):81-85. (Reference #33)

Mailed FIT and Colorectal Cancer Screening Outreach

1. Issaka RB, Taylor P, Baxi A, Inadomi JM, Ramsey SD, Roth J. Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic. *JAMA Netw Open.* 2021 Apr 1;4(4):e216454. doi: 10.1001/jamanetworkopen.2021.6454. PMID: 33843997; PMCID: PMC8042520. (Reference #79)
2. Baldwin LM, Schneider JL, Schwartz M, et al. First-year implementation of mailed FIT colorectal cancer screening programs in two Medicaid/Medicare health insurance plans: qualitative learnings from health plan quality improvement staff and leaders. *BMC Health Services Research.* 2020;20(1):1-13. DOI: 10.1186/s12913-019-4868-5. PMID: 32085767. PMCID: PMC7035739.
3. Castañeda, SF, Bharti B, Rojas M, et al. Outreach and Inreach Strategies for Colorectal Cancer Screening Among Latinos at a Federally Qualified Health Center: A Randomized Controlled Trial, 2015–2018. *American Journal of Public Health.* 2020;110(4):587. DOI: 10.2105/AJPH.2019.305524. PMID: 32078353. PMCID: PMC7067111
4. Coronado GD, Schneider JL, Green BB, et al. Health plan adaptations to a mailed outreach program for colorectal cancer screening among Medicaid and Medicare enrollees: the BeneFIT study. *Implement Sci.* 2020 Sep 15;15(1):77. doi: 10.1186/s13012-020-01037-4. PMID: 32933525; PMCID: PMC7493880.
5. Gupta S, Coronado GD, Argenbright K, et al. Mailed Fecal Immunochemical Test Outreach for Colorectal Cancer Screening: Summary of a Centers for Disease Control and Prevention-Sponsored Summit. *CA: A Cancer Journal for Clinicians.* 2020; 70(4):283-298. (Reference #26)
6. Issaka RB, Somsouk M. Colorectal Cancer Screening and Prevention in the COVID-19 Era. *JAMA Health.* 2020;1(5):e200588. DOI: 10.1001/jamahealthforum.2020.0588.
7. Issaka RB, Akinsoto NO, Strait E, Chaudhari V, Flum DR, Inadomi JM. Effectiveness of a mailed fecal immunochemical test outreach: a Medicare Advantage pilot study. *Therapeutic Advances in Gastroenterology.* January 2020. doi:10.1177/1756284820945388.
8. Singal AG. Fecal Immunochemical Test (FIT) and Colonoscopy Outreach. National Cancer Institute Evidence-Based Cancer Control Programs (EBCCP). <https://ebccp.cancercontrol.cancer.gov/programDetails.do?programId=26900022> Last updated November 2, 2020. Accessed August 1, 2021. (Reference #52)
9. Somsouk M, Rachocki C, Mannalithara A, et al. Effectiveness and cost of organized outreach for colorectal cancer screening: a randomized, controlled trial. *J Natl Cancer Inst.* 2020;112(3):305-313. DOI:10.1093/jnci/djz110. PMID: 31187126. PMCID: PMC7017601.
10. Chido-Amajuoyi OG, Sharma A, Talluri R, Tami-Maury I, Shete S. Physician-office vs home uptake of colorectal cancer screening using FOBT/FIT among screening-eligible US adults. *Cancer Medicine.* 2019;8(17):7408-7418. DOI: 10.1002/cam4.2604. PMID: 31637870. PMCID: PMC6885889.
11. Fletcher RH. Colonoscopy outreach increased CRC screening more than FIT outreach; both were better than usual care. *Ann Intern Med.* 2017;167(12):JC65. DOI: 10.7326/ACPJC-2017-167-12-065. PMID: 29255855. PMCID: PMC6583619.
12. Singal AG, Gupta S, Skinner CS, et al. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A

Appendix D

Annotated Bibliography

Randomized Clinical Trial. *JAMA*. 2017;318(9):806-815. DOI: 10.1001/jama.2017.11389. PMID: 28873161. PMCID: PMC5648645.

Follow-Up of Abnormal FIT or FOBT Results

1. Coronado GD, Kihn-Stang, A, Slaughter MT, et al. Follow-up colonoscopy after an abnormal stool-based colorectal cancer screening result: analysis of steps in the colonoscopy completion process. *BMC Gastroenterol* 21, 356 (2021). <https://doi.org/10.1186/s12876-021-01923-1> (Brief Reference #4)
2. Issaka RB, Bell-Brown A, Snyder C, et al. Perceptions on Barriers and Facilitators to Colonoscopy Completion After Abnormal Fecal Immunochemical Test Results in a Safety Net System. *JAMA Netw Open*. 2021;4(8):e2120159. Published 2021 Aug 2. doi:10.1001/jamanetworkopen.2021.20159 (Brief Reference #1)
3. Jaklevic MC. The Push for Timely Follow-up After Abnormal At-home Colon Cancer Screening Results. *JAMA*. 2021;325(15):1492–1493. doi:10.1001/jama.2021.2018
4. Miguel SM, Demb J, Martinez ME, Gupta S, May FP. Time to Colonoscopy After Abnormal Stool-Based Screening and Risk for Colorectal Cancer Incidence and Mortality. *Gastroenterology*. 2021; 160(6): 1997-2005 (Reference #92)
5. Cusumano VT, Corona E, Partida D, Yang L, Yu C, May FP. Patients without colonoscopic follow-up after abnormal fecal immunochemical tests are often unaware of the abnormal result and report several barriers to colonoscopy. *BMC Gastroenterology*. 2020;20(1):115. DOI: 10.1186/s12876-020-01262-7. PMID: 32306919. PMCID: PMC7168865.
6. Issaka RB, Rachocki C, Huynh MP, Chen E, Somsouk M. Standardized workflows improve colonoscopy follow-up after abnormal fecal immunochemical tests in a safety-net system. *Dig Dis Sci*. 2020;66(3):768-774. DOI:10.1007/s10620-020-06228-z. PMID: 32236885.
7. Anath A Flugelman, Nili Stein, Ori Segol, Idit Lavi, Lital Keinan-Boker, Delayed Colonoscopy Following a Positive Fecal Test Result and Cancer Mortality, *JNCI Cancer Spectrum*, Volume 3, Issue 2, June 2019, pkz024, <https://doi.org/10.1093/jncics/pkz024> (Brief Reference #21)
8. Beshara, A., Ahoroni, M., Comanester, D., Vilkin, A., Boltin, D., Dotan, I., Niv, Y., Cohen, A.D. and Levi, Z. (2020), Association between time to colonoscopy after a positive guaiac fecal test result and risk of colorectal cancer and advanced stage disease at diagnosis. *Int. J. Cancer*, 146: 1532-1540. <https://doi.org/10.1002/ijc.32497> (Brief Reference #19)
9. Lee YC, Fann JC, Chiang TH, Chuang SL, Chen SL, Chiu HM, Yen AM, Chiu SY, Hsu CY, Hsu WF, Wu MS, Chen HH. Time to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests. *Clin Gastroenterol Hepatol*. 2019 Jun;17(7):1332-1340.e3. doi: 10.1016/j.cgh.2018.10.041. Epub 2018 Nov 1. PMID: 30391435. (Brief Reference #20)
10. O'Connor EA, Nielson CM, Petrik AF, Green BB, Coronado, GD. Prospective Cohort study of Predictors of Follow-Up Diagnostic Colonoscopy from a Pragmatic Trial of FIT Screening. *Scientific Reports*. 2020;10(1):2441. DOI: 10.1038/s41598-020-59032-0. PMID: 32051454. PMCID: PMC7016148.
11. Orsak G, Allen CM, Singh KP, McGaha P. Predictors of Nonadherence to Colonoscopy Following a Positive Fecal Immunochemical Test in a Primarily Rural Region of Northeast Texas. *Texas Public Health Journal*. 2020;71(3):19-23
12. Selby, Kevin MD, MAS1,2; Jensen, Christopher D. PhD1; Zhao, Wei K. MPH1; Lee, Jeffrey K. MD, MAS1; Slam, Arielle MPH, MBA3; Schottinger, Joanne E. MD4; Bacchetti, Peter PhD5; Levin, Theodore R. MD6; Corley, Douglas A. MD, PhD1 Strategies to Improve

Appendix D

Annotated Bibliography

Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study, *Clinical and Translational Gastroenterology*: February 2019 - Volume 10 - Issue 2 - p e00010 doi: 10.14309/ctg.0000000000000010 (Brief Reference #3)

13. Presentation at NCCRT Workshop by Fola May, MD, PhD, of UCLA Jonsson Comprehensive Cancer Center and the Veterans Health Administration (Brief Reference #14)
14. Clinician's Reference: Stool-Based Tests for Colorectal Cancer Screening Web site. http://nccrt.org/wp-content/uploads/dlm_uploads/IssueBrief_FOBT_CliniciansRef-09282019.pdf. 2019. (Reference #31)
15. Linda Rabeneck, MD MPH FRCPC. Ensuring Follow-up to Abnormal gFOBT/FIT (Brief Reference #9)
16. Song LD, Newhouse JP, Garcia DX, Hsu J, Garcia-De-Albeniz X. Changes in screening colonoscopy following Medicare reimbursement and cost-sharing changes. *Health Services Research*. 2019;54(4):839-850. DOI: 10.1111/1475-6773.13150. PMID: 30941767. PMCID: PMC6606542.
17. Dalton, ARH. Incomplete diagnostic follow-up after a positive colorectal cancer screening test: a systematic review. *Journal of Public Health*. 2018;40(1):e46-e58. DOI: 10.1093/pubmed/fdw147. PMID: 28069989.
18. Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Schottinger JE, Marks AR, Zhao WK, Ghai NR, Lee AT, Contreras R, Quesenberry CP, Fireman BH, Levin TR. Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis. *JAMA*. 2017 Apr 25;317(16):1631-1641. doi: 10.1001/jama.2017.3634. PMID: 28444278; PMCID: PMC6343838. (Brief Reference #2)
19. Daly JM, XU Y, Levy BT. Which Fecal Immunochemical Test Should I Choose? *J Prim Care Community Health*. 2017 Apr 1:2150131917705206. doi: 10.1177/2150131917705206. [Epub ahead of print] (Reference #37)
20. Doubeni CA, Corley DA, Levin TR. Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test. *JAMA*. 2017;318(5):483. DOI: 10.1001/jama.2017.9312. PMID: 28763543; PMCID: PMC6197858.
21. Thamarasseril S, Bhuket T, Chan C, Liu B, Wong R. The Need for an Integrated Patient Navigation Pathway to Improve Access to Colonoscopy After Positive Fecal Immunochemical Testing: A Safety-Net Hospital Experience. *Journal of Community Health*. 2017;42(3):551-557. DOI: 10.1007/s10900-016-0287-2. PMID: 27796633.
22. Oluloro A, Petrik A, Turner A, et al. Timeliness of Colonoscopy After Abnormal Fecal Test Results in a Safety Net Practice. *Journal of Community Health*. 2016;41(4):864-870. DOI: 10.1007/s10900-016-0165-y. PMID: 26874943. PMCID: PMC5400284.
23. Chen LA, Santos S, Jandorf L, et al. A program to enhance completion of screening colonoscopy among urban minorities. *Clin Gastroenterol Hepatol*. 2008;6(4):443-450. doi: 10.1016/j.cgh.2007.12.009; 10.1016/j.cgh.2007.12.009. (Reference #64)

Appendix D
Annotated Bibliography

Multitarget Stool DNA (mt-sDNA)

1. Cologuard. US National Library of Medicine. Accessed March 30, 2021. <https://medlineplus.gov/ency/article/007747.htm> (Brief Reference #13)
2. Imperiale TF, Kisiel JB, Itzkowitz SH, et al. Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45–49 Year-Olds: A Cross-Sectional Study. *Cancer Prev Res*. 2021 April; 14(4):489-496. doi: 10.1158/1940-6207.CAPR-20-0294.
3. Jaklevic MC. Pandemic Spotlights In-home Colon Cancer Screening Tests. *JAMA*. 2021;325(2):116–118. doi:10.1001/jama.2020.22466
4. Redwood DG, Dinh TA, Kisiel JB, et al. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People. *Mayo Clin Proc*. 2021 May; 96(5):1203-1217. doi: 10.1016/j.mayocp.2020.07.035. Epub 2021 Apr 9. PMID: 33840520.
5. Hathway JM, Miller-Wilson LA, Jensen IS, et al. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. *J Med Econ*. 2020 Jun; 23(6):581-592. doi: 10.1080/13696998.2020.1730123. Epub 2020 Apr 11. Erratum in: *J Med Econ*. 2021 Jan-Dec;24(1):781. PMID: 32063100.
6. Kisiel, John B; Limburg, Paul J. Colorectal Cancer Screening With the Multitarget Stool DNA Test, *The American Journal of Gastroenterology*: November 2020; 115(11): 1737-1740. doi: 10.14309/ajg.00000000000009688.
7. Sharma T. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults. *Public Health*. 2020 May;182:70-76. doi: 10.1016/j.puhe.2020.01.021. Epub 2020 Mar 13. PMID: 32179290.
8. A Stool DNA Test (Cologuard) for Colorectal Cancer Screening. *JAMA*. 2014;312(23):2566. doi:10.1001/jama.2014.15746
9. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. *N Engl J Med*. 2014;370:1287-1297. (Reference #41)
10. Itzkowitz SH. Incremental advances in excremental cancer detection tests. *J Natl Cancer Inst* 2009;101:1225–1227 (Reference #1)

Colorectal Cancer Screening Guidelines & Statistics

1. American Cancer Society. *Cancer Facts & Figures 2022*. Atlanta: American Cancer Society; 2022. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf> (Reference #2)
2. National program grantee data. 2021 Health Center Data Web site. <https://data.hrsa.gov/tools/data-reporting/program-data/national>. Accessed August 25, 2022. (Reference #15)
3. US Preventive Services Task Force, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021;325(19):1965-1977. DOI: 10.1001/jama.2021.6238. PMID: 34003218.
4. Colorectal Cancer: Screening. U.S. Preventive Services Task Force. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening#fullrecommendationstart>. Last updated May 18, 2021. Accessed July 28, 2021.

Appendix D

Annotated Bibliography

5. Bureau of primary health care: BPHC uniform data system manual. Health Resources and Services Administration. April 7, 2021 (Reference #21)
6. American Cancer Society. *Cancer Facts & Figures 2021*. Atlanta: American Cancer Society; 2021. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf> (Reference #2)
7. American Cancer Society Guidelines for Colorectal Cancer Screening. American Cancer Society. <https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html>. Last updated November 17, 2020. Accessed July 28, 2021.
8. Behavioral Risk Factor Surveillance System Survey Data. Centers for Disease Control and Prevention. <https://www.cdc.gov/brfss/index.html>. Last updated August 31, 2020. Accessed July 28, 2021.
9. American Cancer Society. *Cancer Facts & Figures 2020*. Atlanta: American Cancer Society; 2020. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf>
10. National program grantee data. 2020 Health Center Data Web site. <https://data.hrsa.gov/tools/data-reporting/program-data/national>. Accessed August 17, 2021. (Reference #14)
11. Gupta S, Lieberman D, Anderson J, et al. Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer, *The American Journal of Gastroenterology*. March 2020 - Volume 115 - Issue 3 - p 415-434 doi: 10.14309/ajg.0000000000000544 (Reference #75)
12. Siegel R, Miller KD, Sauer AG, et al. Colorectal Cancer Statistics, 2020. *CA Cancer J Clin*. 2020;70(3):145-164. DOI: 10.3322/caac.21601. (Reference #17)
13. National program grantee data. 2019 Health Center Data Web site. <https://data.hrsa.gov/tools/data-reporting/program-data/national>. Accessed July 28, 2021 (Reference #13)
14. Krigel A, Prasad VK, Lebwohl B. News Coverage of the American Cancer Society's Update to Colorectal Cancer Screening Guidelines. *Mayo Clinic Proceedings*. 2020;95(3):617-618. DOI: 10.1016/j.mayocp.2019.12.016. PMID: 32138893.
15. Ratushnyak S, Hoogendoorn M, van Baal PHM. Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained. *American Journal of Preventive Medicine*. 2019;57(6):792-799. DOI: 10.1016/j.amepre.2019.07.027. PMID: 31753260.
16. Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [2012, 2014, 2016, 2018, 2020]. (Reference #16)
17. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin*. 2019;69(3):184-210. DOI: 10.3322/caac.21557. PMID: 30875085.
18. Sur D, Colceriu M, Sur G, Floca E, Dascal L, Irimie A. Colorectal cancer: evolution of screening strategies. *Med Pharm Rep*. 2019;92(1):21-24. doi:10.15386/cjmed-1104.
19. National Center for Health Statistics, Division of Health Interview Statistics. National Health Interview Survey Public Use Data File 2018. In. Centers for Disease Control and Prevention. Hyattsville, MD.2019.

Appendix D

Annotated Bibliography

20. Kaiser V. Implementing Colon Cancer Screening Guidelines Into the Primary Care Setting. *Gastroenterology Nursing*. 2018;41(6):477-490. DOI: 10.1097/SGA.0000000000000347. PMID: 30489404.
21. Centers for Disease Control and Prevention. Measuring Breast, Cervical and Colorectal Cancer Screening Rates in Health System Clinics: Guidance Document. March 2018. <https://www.cdc.gov/cancer/nbccedp/pdf/measuring-cancer-screening-rates-508.pdf> (Reference #25)
22. Simonson C. Colorectal Cancer – An Update for Primary Care Nurse Practitioners. *The Journal for Nurse Practitioners*. 2018;14(4):344-350. DOI: 10.1016/j.nurpra.2017.12.030
23. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA: A Cancer Journal for Clinicians*. 2018;68(4):250-281. DOI:10.3322/caac.21457. PMID: 29846947.
24. Colorectal Cancer Screening. National Committee for Quality Assurance. <http://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality/2017-table-of-contents/colorectal-cancer/colorectal-cancer> (Reference #18)
25. Brenner H, Zwink N, Ludwig L, Hoffmeister M. Should Screening Colonoscopy Be Offered From Age 50? *Deutsches Aerzteblatt International*. 2017;114(6):94-100. DOI: 3238/arztebl.2017.0094. PMID: 28266302. PMCID: PMC5341112.
26. Screening for Colorectal Cancer: Recommendation Statement. *American Family Physician*. 2017;95(4):Online. PMID: 28290629.
27. Mahon SM. Colorectal cancer screening: Using evidence-based guidelines. *Nurse Practitioner*. 2017;42(10):18-26. DOI: 10.1097/01.NPR.0000524663.78727.4e. PMID: 28926493.
28. Samadder N, Jasperson K, Burt R. Hereditary and Common Familial Colorectal Cancer: Evidence for Colorectal Screening. *Digestive Diseases & Sciences*. 2015;60(3):734-747. DOI: 10.1007/s10620-014-3465-z. PMID: 25501924.
29. Schroy PC, Caron SE, Sherman BJ, Heeren TC, Battaglia TA. Risk assessment and clinical decision making for colorectal cancer screening. *Health Expectations*. 2015;18(5):1327-1338. DOI: 10.1111/hex.12110. PMID: 23905546. PMCID: PMC4213312.
30. Steen A, Knudsen AB, Hees F, et al. Optimal Colorectal Cancer Screening in States' Low-Income, Uninsured Populations-The Case of South Carolina. *Health Services Research*. 2015;50(3):768-789. DOI: 10.1111/1475-6773.12246. PMID: 25324198. PMCID: PMC4450929.

Social Risk Factors in Colorectal Health

1. Balzora S, Issaka RB, Anyane-Yeboah A, Gray DM 2nd, May FP. Impact of COVID-19 on colorectal cancer disparities and the way forward. *Gastrointest Endosc*. 2020 Oct; 92(4):946-950. doi: 10.1016/j.gie.2020.06.042. Epub 2020 Jun 20. PMID: 32574570; PMCID: PMC7529970.
2. Carethers JM, Doubeni CA. Causes of socioeconomic disparities in colorectal cancer and intervention framework and strategies. *Gastroenterology*. 2020;158(2):354-367. DOI: 10.1053/j.gastro.2019.10.029. PMID: 31682851. PMCID: PMC6957741.
3. Gawron AJ, Kaltenbach T, Dominitz JA. The Impact of the Coronavirus Disease-19 Pandemic on Access to Endoscopy Procedures in the VA Healthcare System. *Gastroenterology*. 2020;159(4):1216-1220.e1. doi:10.1053/j.gastro.2020.07.033 (Reference #78)

Appendix D

Annotated Bibliography

4. Rabeneck L, Chiu HM, Senore C. International perspective on the burden of colorectal cancer and public health effects. *Gastroenterology*. 2020;158(2):447-452. DOI: 10.1053/j.gastro.2019.10.007. PMID: 31622620.
5. Lee E, Natipagon-Shah B, Sangsanoi-Terkchareon S, Warda US, Lee S. (2019). Factors Influencing Colorectal Cancer Screening Among Thais in the U.S. *Journal of Community Health*. 2019;44(2):230-237. DOI: 10.1007/s10900-018-0578-x. PMID: 30341745.
6. Muthukrishnan M, Arnold LD, James AS. Patients' self-reported barriers to colon cancer screening in federally qualified health center settings. *Prev Med Rep*. 2019;15:100896. Published 2019 May 15. doi:10.1016/j.pmedr.2019.100896
7. Semega J, Kollar M, Creamer J, Mohanty A. Current Population Reports. Income and Poverty in the United States: 2018. US Census Bureau. <https://www.census.gov/content/dam/Census/library/publications/2019/demo/p60-266.pdf>. Issued September 2019. Last updated June 2020. Accessed July 28, 2021.
8. Cossu G, Saba L, Minerba L, Mascalchi M. Colorectal Cancer Screening: The Role of Psychological, Social and Background Factors in Decision-making Process. *Clin Pract Epidemiol Ment Health*. 2018;14:63-69. Published 2018 Mar 21. doi:10.2174/1745017901814010063
9. Sineshaw HM, Ng K, Flanders WD, Brawley OW, Jemal A. Factors that contribute to differences in survival of black vs white patients with colorectal cancer. *Gastroenterology*. 2018;154:906-915.e7. DOI: 10.1053/j.gastro.2017.11.005. PMID: 29146523. PMCID: PMC5847437.
10. Nagelhout E, Comarell K, Samadder N, Wu Y. Barriers to Colorectal Cancer Screening in a Racially Diverse Population Served by a Safety-Net Clinic. *Journal of Community Health*. 2017;42(4):791-796. DOI: 10.1007/s10900-017-0319-6. PMID: 28168395. PMCID: PMC5517041.
11. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388(10053):1459-1544. DOI: 10.1016/S0140-6736(16)31012-1. PMID: 27733281. PMCID: PMC5388903.
12. May FP, Almario CV, Ponce N, Spiegel BM. Racial minorities are more likely than whites to report lack of provider recommendation for colon cancer screening. *The American journal of gastroenterology*. 2015;110(10):1388. [PubMed] [Google Scholar] (Reference #12)
13. Wallace K, Hill EG, Lewin DN, et al. Racial disparities in advanced-stage colorectal cancer survival. *Cancer Causes & Control*. 2013;24(3):463-471. [PMC free article] [PubMed] [Google Scholar] (Reference #11)
14. Doubeni CA, Laiyemo AO, Major JM, Schootman M, Lian M, Park Y, Graubard BI, Hollenbeck AR, Sinha R. Socioeconomic status and the risk of colorectal cancer: an analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study. *Cancer*. 2012 Jul 15;118(14):3636-44. doi: 10.1002/cncr.26677. Epub 2012 Jan 3. Erratum in: *Cancer*. 2013 Jan 15;119(2):467-9. PMID: 22898918; PMCID: PMC3422782.
15. Jernigan JC, Trauth JM, Neal-Ferguson D, Cartier-Ulrich C. Factors that influence cancer screening in older African American men and women: Focus group findings. *Fam Community Health*. 2001;24(3):27- 33. (Reference #83)
16. Weitzman ER, Zapka J, Estabrook B, Goins KV. Risk and reluctance: Understanding impediments to colorectal cancer screening. *Prev Med*. 2001;32(6):502-513. doi: 10.1006/pmed.2001.0838. (Reference #84)

Appendix D
Annotated Bibliography

Patient Navigation Role in CRC Screening

1. DeGroff A, Gressard L, Glover-Kudon R, et al. Assessing the implementation of a patient navigation intervention for colonoscopy screening. *BMC Health Services Research*. 2019;19(1):803. DOI: 10.1186/s12913-019-4601-4. PMID: 31694642. PMCID: PMC6833190.
2. Phillips S, Villalobos AVK, Crawbuck GSN, Pratt-Chapman M. In their own words: patient navigator roles in culturally sensitive cancer care. *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*. 2019;27(5):1655-1662. DOI: 10.1007/s00520-018-4407-7. PMID: 30109486. PMCID: PMC6449285.
3. Sunny A, Rustveld L. The Role of Patient Navigation on Colorectal Cancer Screening Completion and Education: a Review of the Literature. *Journal of Cancer Education: The Official Journal of the American Association for Cancer Education*. 2018;33(2):251-259. DOI: 10.1007/s13187-016-1140-0. PMID: 27878766.
4. Rice K, Gressard L, DeGroff A, Gersten J, Robie J, Leadbetter S, Glover-Kudon R, Butterly L. Increasing colonoscopy screening in disparate populations: Results from an evaluation of patient navigation in the New Hampshire Colorectal Cancer Screening Program. *Cancer*. 2017 Sep 1;123(17):3356-3366. doi: 10.1002/cncr.30761. Epub 2017 May 2. PMID: 28464213; PMCID: PMC5892823. (Reference #60)
5. DeGroff A, Schroy PC 3rd, Morrissey KG, et al. Patient Navigation for Colonoscopy Completion: Results of an RCT. *American Journal of Preventive Medicine*. 2017;53(3):363-372. DOI: 10.1016/j.amepre.2017.05.010. PMID: 28676254.
6. Domingo JB, Braun KL. Characteristics of Effective Colorectal Cancer Screening Navigation Programs in Federally Qualified Health Centers: a Systematic Review. *Journal of Health Care for the Poor & Underserved*. 2017;28(1):108-126. DOI: 10.1353/hpu.2017.0013. PMID: 28238992. PMCID: PMC5487219.
7. Freund KM. Implementation of evidence-based patient navigation programs. *Acta Oncologica (Stockholm, Sweden)*. 2017;56(2), 123-127. DOI: 10.1080/0284186X.2016.1266078. PMID: 28033027.
8. Martin RL, Tully M, Kos A, et al. Increasing Colorectal Cancer Screening at an Urban FQHC Using iFOBT and Patient Navigation. *Health Promotion Practice*. 2017;18(5):741-750. DOI: 10.1177/1524839917705127. PMID: 28812930.
9. Reuland DS, Brenner AT, Hoffman R, et al. Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population: A Randomized Clinical Trial. *JAMA Internal Medicine*. 2017;177(7):967-974. DOI: 10.1001/jamainternmed.2017.1294. PMID: 28505217. PMCID: PMC5710456.
10. Allary C, Bourmaud A, Tinquaut F, et al. ColoNav: patient navigation for colorectal cancer screening in deprived areas - Study protocol. *BMC cancer*. 2016;16:416. DOI: 10.1186/s12885-016-2469-9. PMID: 27388807. PMCID: PMC4936239.
11. Percac-Lima S, Ashburner JM, Zai AH, et al. Patient Navigation for Comprehensive Cancer Screening in High-Risk Patients Using a Population-Based Health Information Technology System: A Randomized Clinical Trial. *JAMA Internal Medicine*. 2016;176(7):930-937. DOI: 10.1001/jamainternmed.2016.0841. PMID: 27273602.
12. Rohan EA, Slotman B, DeGroff A, Morrissey KG, Murillo J, Schroy P. Refining the Patient Navigation Role in a Colorectal Cancer Screening Program: Results From an Intervention Study. *Journal of the National Comprehensive Cancer Network*. 2016;14(11):1371-1378. DOI: 10.6004/jnccn.2016.0147. PMID: 27799508. PMCID: PMC5419036.

Appendix D

Annotated Bibliography

13. Escoffery C, Fernandez ME, Vernon SW. Patient Navigation in a Colorectal Cancer Screening Program. *Journal of Public Health Management and Practice*. 2015;21(5):433-440. PMID: 25140407. PMCID: PMC4618371.
14. Horne HN, Phelan-Emrick D, Pollack CE, et al. Effect of patient navigation on colorectal cancer screening in a community-based randomized controlled trial of urban African American adults. *Cancer Causes & Control*. 2015;26(2):239-246. DOI: 10.1007/s10552-014-0505-0. PMID: 25516073. PMCID: PMC4370183.
15. Post DM, McAlearney AS, Young GS, Krok-Schoen J, Plascak JJ, Paskett ED. Effects of Patient Navigation on Patient Satisfaction Outcomes. *Journal of Cancer Education: The Official Journal of the American Association for Cancer Education*. 2015;30(4):728-735. DOI: 10.1007/s13187-014-0772-1. PMID: 25510369. PMCID: PMC7217374.
16. Wilson FA, Villarreal R, Stimpson JP, Pagán JA. Cost-effectiveness analysis of a colonoscopy screening navigator program designed for Hispanic men. *Journal of Cancer Education: The Official Journal of the American Association for Cancer Education*. 2015;30(2):260-267. DOI: 10.1007/s13187-014-0718-7. PMID: 25168070.
17. Lagarde SP. No One Left Behind: The Road to 80% by 2018. *Clinical Gastroenterology and Hepatology*. 2014;12(8):1212-1215. DOI: 10.1016/j.cgh.2014.06.001. PMID: 25038608. (Reference #65)
18. New Hampshire Colorectal Cancer Screening Program Patient Navigation Model for Increasing Colonoscopy Quality and Completion A Replication Manual. https://www.cdc.gov/cancer/crccp/pdf/nhcrisp_pn_manual.pdf (Reference #49)
19. Degroff A, Coa K, Morrissey KG, Rohan E, Slotman B. Key considerations in designing a patient navigation program for colorectal cancer screening. *Health Promot Pract*. 2013. doi: 10.1177/1524839913513587. <http://sagepub.com/content/early/2013/12/19/1524839913513587> (Reference #59)
20. Colonoscopy Patient Navigator: A Resource Guide to Help You Get Started. New York City Government <https://www1.nyc.gov/assets/doh/downloads/pdf/cancer/colonoscopy-patient-navigator-guide.pdf>
21. **Colorado Patient Navigator Training Program** patientnavigatortraining.org/
22. Patient Navigation Research Program Center to Reduce Cancer Health Disparities, National Cancer Institute crchd.cancer.gov/pnp/pnpr-index.html
23. Braun KL, Kagawa-Singer M, Holden AE, et al. Cancer patient navigator tasks across the cancer care continuum. *J Health Care Poor Underserved*. 2012;23(1):398-413. doi: 10.1353/hpu.2012.0029; 10.1353/hpu.2012.0029. (Reference #47)
1. Christie J, Itzkowitz S, Lihau-Nkanza I, Castillo A, Redd W, Jandorf L. A randomized controlled trial using patient navigation to increase colonoscopy screening among low-income minorities. *J Natl Med Assoc*. 2008;100(3):278-284. (Reference #63)
24. Jandorf L, Gutierrez Y, Lopez J, Christie J, Itzkowitz SH. Use of a patient navigator to increase colorectal cancer screening in an urban neighborhood health clinic. *J Urban Health*. 2005;82(2):216-224. doi: 10.1093/jurban/jti046. (Reference #65)
25. https://nccrt.org/wp-content/uploads/dlm_uploads/Links-of-Care-Report_2020.06.26.pdf (Reference #71)

Electronic Health Records

Appendix D

Annotated Bibliography

1. Information on Meaningful Use of Electronic Health Records – Centers for Disease Control and Prevention [cdc.gov/ehrmeaningfuluse](https://www.cdc.gov/ehrmeaningfuluse)
2. HRSA Reporting and Technical Assistance bphc.hrsa.gov/healthcenterdatastatistics/reporting/index.html
3. <https://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Certification> (Brief Reference #24)
4. HHS 45 CFR Parts 171 and 171 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program. <https://www.govinfo.gov/content/pkg/FR-2020-05-01/pdf/2020-07419.pdf> (Brief Reference #25)

Practice Management

1. National Cancer Institute Research Tested Intervention Programs (RTIP) – list of evidence-based screening programs, many of which can be adopted and implemented by CHCs rtips.cancer.gov/rtips/programSearch.do
2. CDC Guide to Community Preventive Services Website – resource to help you choose programs and policies to improve health and prevent disease in your community thecommunityguide.org/index.html
1. Cancer Coalition of South Georgia sgacancer.org
3. Operation Access operationaccess.org
4. New York Citywide Colon Cancer Control Coalition c5nyc.org
5. CDC Colorectal Cancer Control Program (CRCCP) cdc.gov/cancer/crccp/

Cancer Prevention

1. Kelloff GJ, Schilsky RL, Alberts DS, et al. Colorectal adenomas: A prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res. 2004;10(11):3908-3918. doi: 10.1158/1078-0432.CCR-03-0789. (Reference #3)
1. Bernstein CN, Blanchard JF, Kliever E, Wajda A. Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer. 2001;91(4):854-862. (Reference #76)

Costs & Cost Effectiveness

1. Mariotto AB, Enewold L, Zhao JX, Zeruto CA, Yabroff KR. Medical Care Costs Associated with Cancer Survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1304-12.
2. <https://www.fightcancer.org/releases/house-passes-fix-medicare-cost-sharing-loophole-colorectal-cancer-screenings> (Reference #45, Brief Reference #44)
3. Section 4104: Coverage of preventive health services. Patient Protection and Affordable Care Act (HR3590) Web site. <https://www.congress.gov/bill/111th-congress/house-bill/3590>. Accessed March 16, 2022. (Reference #48, Brief Reference #43)
4. Chapter 18 - preventive and screening services. Medicare Claims Processing Manual. Web site. <https://www.hhs.gov/guidance/document/medicare-claims-processing->

Appendix D

Annotated Bibliography

manual-chapter-18-preventive-and-screening-services. Updated 2019. Accessed March 16, 2022. (Brief Reference #42)

5. Subramanian S, Tangka FK, Hoover S, Cole-Beebe M, Joseph D, DeGroff A. Comparison of Program Resources Required for Colonoscopy and Fecal Screening: Findings From 5 Years of the Colorectal Cancer Control Program. *Prev Chronic Dis* 2019;16:180338. DOI: <http://dx.doi.org/10.5888/pcd16.18033> (Reference #7)
6. Chen CT, Li L, Brooks G, Hassett M, Schrag D. Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death. *Health Serv Res*. 2018;53(4):2118-2132. doi:10.1111/1475-6773.12745. (Reference #6)
7. http://nccrt.org/wp-content/uploads/dlm_uploads/CRC-Screening-Continuum-Coverage-Issues-Brief-Private-Health-Plans-April2018.pdf (Brief Reference #6)
8. Sutton ER, Walling S, Kimbrough C, Borkhetaria N, Jones W, Sutton B. Cost Analysis of Free Colonoscopies in an Uninsured Population at Increased Risk for Colorectal Cancer. *J Am Coll Surg*. 2016 Jul;223(1):129-32. doi: 10.1016/j.jamcollsurg.2016.04.035. Epub 2016 May 26. PMID: 27238000. (Reference #73)
9. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. *Epidemiol Rev*. 2011;33(1):88-100. doi: 10.1093/epirev/mxr004; 10.1093/epirev/mxr004. (Reference #43)